The market for migraine medications has heated up in the last year with a new class of treatments hitting the scene.
Demand has been strong for Amgen’s Aimovig, which works by targeting calcitonin gene-related peptide (CGRP) antibodies, since it was approved by the FDA in May. Now, Teva Pharmaceutical’s Ajovy has also been given the green light — and sales are also expected to be high in the traditionally underserved market for migraine treatments.
Like Aimovig, Ajovy is an injectable treatment that blocks CGRP antibodies to prevent migraines. But so far, it’s the only treatment with monthly and quarterly dosing options.
About 39 million Americans struggle with migraines, and analysts predict that the market for anti-CGRP antibodies could reach $4.5 billion by 2020.
Eli Lilly & Co. is also developing a similar medication that the company hopes will win approval by the end of this month.
[javascriptSnippet]